## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

| OMB APPROVAL       |           |  |  |  |  |  |
|--------------------|-----------|--|--|--|--|--|
| OMB Number:        | 3235-0287 |  |  |  |  |  |
| Estimated average  | burden    |  |  |  |  |  |
| hours per response | 0.5       |  |  |  |  |  |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| (Print or Type                                       | Responses)  |  |   |   |       |                             |   |                              |  |                          |  |  |  |                             |                               |  |
|--|---|--|---|---|-------|-----------------------------|---|------------------------------|--|--------------------------|--|--|--|-----------------------------|-------------------------------|--|
| 1. Name and<br>Siffert Joac                          |   | eporting Person*                           |   | 2. Issuer Name and Ticker or Trading Symbol ABEONA THERAPEUTICS INC. [ABEO] |       |                             |   | _X_                          | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)XDirector10% Owner  |                          |  |  |  |                             |                               |  |
| 1330 AVE<br>FLOOR                                    |   | (First)<br>THE AMERICA                     | ~ ~~~~  | 3. Date of Earliest Transaction (Month/Day/Year) 03/16/2020                 |       |                             |   | X                            | X Officer (give title below) Other (specify below)  Chief Executive Officer  |                          |  |  |  |                             |                               |  |
| NEW YOR  | RK, NY 10   | (Street)                                   |   | 4. If Amendment, Date Original Filed(Month/Day/Year)                        |       |                             |   | _X_1                         | 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person _ Form filed by More than One Reporting Person |                          |  |  |  |                             |                               |  |
| (City)   |   | (State)                                    | (Zip)   |   |       | Ta                          | ble I   | - Non-Der                    | rivati   | ive Securities           | s Acquired,                              | Disposed o   | f, or Benefi   | cially Owned                |                               |  |
| 1.Title of Sec<br>(Instr. 3)                         | curity  |  | 2. Transaction<br>Date<br>(Month/Day/Year                   | ) any   | ion l | Date, if Co                 |   | 8) (                         | (A) or   | r Disposed of (A) or (D) | (D) Own<br>Tran                          | mount of Second Followin saction(s) r. 3 and 4)  |  | C<br>F<br>D<br>O            | wnership<br>orm:<br>irect (D) | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>Instr. 4) |
| Reminder: Re   | eport on a sep  | parate line for each c                     |   | - Derivat   | tive  | Securities A                | Acqu  | Persor<br>in this<br>a curre | formently  |                          | quired to a<br>control na<br>icially Own | respond ur<br>umber.   |  | n contained<br>orm displays |                               | 474 (9-02)   |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)  | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 4. 5. Number of 6. Transaction Code Securities (N                           |       | 6. Date Expiration (Month/D | Expiration Date of Uno<br>(Month/Day/Year) Securi |                              | 7. Title and of Underly Securities (Instr. 3 an  | ing                      |  | 9. Number of<br>Derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction(s) | Ownership<br>Form of<br>Derivative<br>Security:<br>Direct (D)<br>or Indirect | (Instr. 4)                  |                               |  |
|  |   |  |   | Code  | v     | (A)                         | (D)   | Date<br>Exercisab            |  | xpiration<br>Pate        | Title                                    | Amount<br>or<br>Number<br>of Shares  |  | (Instr. 4)                  | (Instr. 4)                    |  |
| Employee<br>Stock<br>Option<br>(right to<br>buy) (2) | \$ 1.45   | 03/16/2020                                 |   | A   |       | 127,704                     |   | (1)                          | 0:   | 3/16/2030                | Common<br>Stock                          | 127,704  | \$ 0   | 127,704                     | D                             |  |

### **Reporting Owners**

|   | Relationships |              |                         |       |  |  |  |
|---|---------------|--------------|-------------------------|-------|--|--|--|
| Reporting Owner Name / Address  | Director      | 10%<br>Owner | Officer                 | Other |  |  |  |
| Siffert Joao MD<br>1330 AVENUE OF THE AMERICAS,<br>33RD FLOOR<br>NEW YORK, NY 10019 | X             |              | Chief Executive Officer |       |  |  |  |

### **Signatures**

| /s/ Joao Siffert                | 03/18/2020 |
|---------------------------------|------------|
| **Signature of Reporting Person | Date       |

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- ( 1) The options will vest 25% on March 16, 2021, and in 36 equal monthly installments thereafter.

Contingent upon stockholder approval of an amendment to the 2015 Equity Incentive Plan (the "2015 Plan") at the Annual Meeting of Stockholders scheduled for May 20, 2020 to increase the number of shares available under the 2015 Plan, Mr. Siffert will also be entitled to an additional grant of 72,296 stock options and a grant of 100,000 shares of restricted stock as soon as practicable after the amendment of the 2015 Plan. The stock options contingent upon stockholder approval will have an exercise price determined at the grant date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.